My Companies
Notification
Account
Log Out
Login
USFDA follow-up inspection at Cipla’s Pithampur facility resulted in seven Form 483 observations, creating regulatory uncertainty and potential remediation risk. The company committed to comprehensive corrective action.
Cipla Receives US FDA Approval For Generic Advair Diskus Inhaler
Cipla Appoints Dinesh Jain Global CFO As Ashish Adukia Moves To Internal Role